Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy.

Autor:	Abdul Qadir Memon A; Department of Pharmacy Practice, Faculty of Pharmacy, University of Karachi, Pakistan., Shamim A; Department of Pharmacy Practice, Faculty of Pharmacy, University of Karachi, Pakistan., Mirza S; Department of Pharmacy Practice, Faculty of Pharmacy, University of Karachi, Pakistan., Osama M; Department of Pharmacy Practice, Faculty of Pharmacy, University of Karachi, Pakistan.; Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Pakistan., Naeem Muhammad I; Department of Pharmacy Practice, Faculty of Pharmacy, University of Karachi, Pakistan.; Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Pakistan., R Wei C; Department of Research and Development, Shing Huei Group, Taipei, Taiwan.
Jazyk:	angličtina
Zdroj:	Cardiovascular & hematological agents in medicinal chemistry [Cardiovasc Hematol Agents Med Chem] 2024 Apr 05. Date of Electronic Publication: 2024 Apr 05.
DOI:	10.2174/0118715257283752240325082733
Abstrakt:	Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy. This review provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten, and the clinical trials of Mavacamten. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu